The European Journal of Heart Failure (EJHF) has reached a high impact factor making it one of the most important cardiology journals. I discuss herein what could be the main causes of such high ranking. Publication of the European Society of Cardiology guidelines for the diagnosis and treatment of acute and chronic heart failure has had the most important role with a number of citations, which has been approximately 10 times that of the other most cited articles of the same year. Other position statements, reviews, design papers, and research articles about landmark topics have given major contributions. With respect to the different clinical presentations, articles about heart failure with preserved ejection fraction and about advanced heart failure have gained many citations. Epidemiology, biomarkers, medical treatment, and devices have attracted most of the interest. In conclusion, being able to look ahead and to publish what is going to become important remains a major challenge. That of EJHF has been a success story, to date, and learning from the past may help to build upon this achievement.
Anytime you start a new job, you are surrounded by people asking you to start something novel. You find plenty of people saying things such as 'Now, it's time for change', 'You must show that now it's you', 'No matter how, but you have to show that you take decisions' … This is not specific. This has happened to me every time. I think we are all spoiled by newspapers and magazines and the need of outstanding news almost every day. We are all expecting bombastic announcements. Then, very often it does not matter if they will be fulfilled or not.
In my case with European Journal of Heart Failure (EJHF), this is not happening and this has a simple cause. What I have inherited is a privilege, an honour, something to continue and, as many know, a lot of work. We know that it is more difficult to say good things than to criticize, but we can all just say good things about EJHF. Based on its impact factor, it is now the best journal about heart failure in the world, and the tenth ranked journal among all 125 cardiology journals in the Thomson Reuters Journal Citation Reports ® (Figure 1 ).
Hence, why not, for a young Editor-in-Chief like me, to try and see the reasons for this success, that is to say to study which were the articles that contributed most to such a high ranking for this journal? These articles are listed in the tables below, and a selection of them has been collected into a virtual issue of EJHF to celebrate the legacy of the previous Editor-in-Chief, Dirk van Veldhuisen. Talking about them and briefly summarizing their content will be a way to describe my highlights in heart failure over the last few years.
Why can I do this here and today? Am I celebrating something else in addition to EJHF? Yes, and these are Stefan Anker and ESC Heart Failure (ESCHF), the new open access journal having Stefan as Editor-in-Chief and Stephan von Haehling and Zoltan Papp as Deputy Editors. On their websites, EJHF and ESCHF are indicated as associated journals. Here I say that they really are. Articles rejected by EJHF can be transferred, upon the Authors' acceptance, to ESCHF. A few articles may be published simultaneously, and we have already had one. 1 The collaboration can then have many other aspects and here is Stefan's request to have me writing a comment about EJHF's last years, a request that I am happy to try to fulfil.
Society of Cardiology (ESC) guidelines for the diagnosis and treatment of acute and chronic heart failure. 2 Looking at Table 3 , showing the top 10 articles issued in 2012, these guidelines have almost 10 times the number of citations than the article which ranked second. These guidelines have set new standards for heart failure diagnosis and treatment. With respect to the classification and diagnosis of heart failure, the role of the left ventricular ejection fraction has been established as well as the practical use of biomarkers. New indications for aldosterone antagonists in patients with NYHA class II symptoms and for ivabradine for symptomatic patients with a heart rate ≥70/min have been established, whereas all the limitations and lack of evidence for the treatment of heart failure with preserved ejection fraction (HFpEF) and acute heart failure were shown. In addition, indications for treatment of co-morbidities, left ventricular assist device implantation and coronary revascularization in patients with heart failure have been thoroughly discussed. 2 Following the guidelines, many other articles have paved our advances in heart failure knowledge and some of them are discussed in the succeeding paragraphs.
The 10 most cited articles from EJHF 
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The two most cited articles are the ESC guidelines for the diagnosis and treatment of acute and chronic heart failure.
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Then, the article that ranks 4th is a state of the art paper regarding the use of natriuretic peptides 4 and that ranking 6th is a large review regarding the biochemistry and physiology of NT-proBNP. 5 Thus, large reviews regarding major topics are the best cited articles of EJHF. Their number of citations does not reach the stellar values of the guidelines but is, at least, comparable to it, at about one-third of what they have reached ( Table 1) .
At the 3rd, 5th, and 10th position of the list of the top 10 articles, we have papers regarding the epidemiology and, in two cases, the costs of heart failure. [6] [7] [8] The years in which they were published were the years in which the impact of heart failure was not so clear. Those articles and, I might say, EJHF itself helped to establish and make clear to the community the importance of this syndrome. The high impact of these articles further shows the importance of having articles based on topics that are broad enough, and likely to be cited in different papers.
Two other articles regard sleep-disordered breathing and cardiac resynchronization therapy (CRT). Sleep-disordered breathing, or sleep apnoea, is still an emerging aspect of heart failure with major trials regarding the potential benefits of its treatment still ongoing. This article showed its high prevalence in a large data base of 700 patients and was among the first to show its importance and relation with heart failure severity. 9 The paper that ranks 7th is a design paper regarding probably the most important trial with CRT, the CArdiac REsynchronisation in Heart Failure study. 10 This finding, that a design paper of a major trial can gather many citations, will be found also in the succeeding paragraphs, when we will consider each year's top 10 most cited articles.
Lastly, the 9th most cited article, comes from an early report of the clinical trials results presented at a recent meeting. 11 The number of citations that this article had was particularly impressive as some of the trials reported there were not published for many years. 12 However, all of this kind of articles, punctually issued by John Cleland after each of these major meetings, were highly cited and gave a major contribution to the initial rise in the impact factor of the journal. It has been discussed whether we should resume such an initiative, but the practice of early online publication of trials by major journals, including ours, has probably made such articles less useful. 
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Inglis SC, Clark RA, McAlister FA et al. 52 Which components of heart failure programmes are effective? A systematic review and meta-analysis of the outcomes of structured telephone support or telemonitoring as the primary component of chronic heart failure management in 8323 patients: Abridged Cochrane Review It is rather impressive to realize how much design papers have contributed to the success of the journal. The results of major landmark trials are often published in the major impact journals. However, the design of such trials still has major interest, either before the trial is accomplished, as they anticipate what are expected as major findings, or when the major results and sub-studies are published. Hence, we have been pleased to find four articles based on trials' design among the 10 most cited articles from the last 3 years.
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What matters more: different clinical presentations, treatment, devices, biomarkers HFpEF, 13, 19, 20, 25, 26 and advanced heart failure 27-31 are major areas of interest and research. We all hope that this will translate into meaningful progress in the treatment of these conditions.
Most cited articles often cover the treatment of heart failure. Articles related to medical treatment, 18, [21] [22] [23] [24] [25] [31] [32] [33] [34] and devices, 28, 29, 35, 36 had major interest. Biomarkers 19, [37] [38] [39] [40] [41] [42] and epidemiology 13, 32, 43, 44 also represent a major area of research and interest for our journal with 7 and 4 articles, which have ranked among the top 10 most cited articles in their years.
Translational science 41, 45, 46 and disease management 14, 16, 17 had three articles each and cardiovascular imaging had two articles 26, 47 among the top 10 most cited articles in any of these last years. No most cited article came from the basic research arena. These last results are particularly impressive if we consider that heart failure is a major aspect of basic science and cardiovascular imaging and that the journals focused on 9 Gomez N, Touihri K, Matheeussen V et al. 27 Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure 46 10 Gotsman I, Shauer A, Zwas DR et al. 25 Vitamin D deficiency is a predictor of reduced survival in patients with heart failure; vitamin D supplementation improves outcome 33 Editorial 53 these topics rank among the most cited cardiology journals. More simply, it may be that EJHF receives less interesting articles about basic science or imaging and, thus, these articles are also less likely to be cited. Any journal must find its main topics and concentrate on them.
In conclusion, being able to look ahead and to publish what is going to become important remains a major challenge. That of EJHF has been a success story, to date, and learning from the past may help to build upon this achievement. 
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